Concarlo Expands Executive Leadership Team with the Appointment of Dr. Krishna Allamneni as Chief Development Officer
Industry veteran will help accelerate Company’s drive to create transformative therapies for drug resistant cancers by controlling the p27 target
Renovacor Announces Data from Pilot Pig Study Showing Successful Cardiac Transduction with REN-001 Delivered Via Low-Dose Retrograde Coronary Sinus Infusion Published in Journal of the American College of Cardiology: Basic to Translational Research
REN-001 delivered locally via low-dose retrograde coronary sinus infusion demonstrated robust, diffuse cardiomyocyte transduction in a large animal heart
ENB Therapeutics Announces Orphan Drug Designation Granted by FDA for ENB-003 for the Treatment of Pancreatic Cancer
ENB-003 is a first in class small molecule therapeutic selectively targeting the ETB receptor – a novel immune checkpoint
Immunome Provides Research & Development Update on Lead Oncology Candidate Targeting IL-38
– Profiling of IL-38 mRNA in over 60 cancer types revealed notably high frequency (60-80%) of IL-38 expression in select solid tumor sub-types of high unmet clinical need –
– Collaboration with Fox Chase Cancer Center to directly confirm IL-38 protein expression in patients –
– Anticipated IND filing in 2H 2022 –
Immunome Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 Subvariant
– Data show that combination of two antibodies in Immunome’s cocktail successfully neutralized the Omicron variant in vivo in hamsters –
– IMM20253 antibody also retained activity against BA.2 subvariant in pseudovirus testing in vitro, with additional testing underway –
Renovacor Reports First Quarter 2022 Financial Results and Provides Corporate Update
REN-001 advancing toward IND submission in the second half of 2022 with the initiation of a Phase I/II clinical trial in BAG3-DCM expected thereafter
Strengthened executive team with appointment of Fred Driscoll as CFO
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results